ViroMed Gene Therapy for Non-Healing Diabetic Foot Ulcers Starts Phase III Trial – Genetic Engineering & Biotechnology News
|
ViroMed Gene Therapy for Non-Healing Diabetic Foot Ulcers Starts Phase III Trial
Genetic Engineering & Biotechnology News The first patient has been dosed in a Phase III trial assessing ViroMed’s VM202, the first pivotal study of a gene therapy indicated for patients with non-healing diabetic foot ulcers (NHU) and concomitant peripheral artery disease (PAD). The Phase 3 … |
Genetic Literacy Project |
What is CRISPR-Cas9, how does gene editing work, who discovered the technique and could it mean we live longer?
The Sun BREAKTHROUGHS in gene editing have paved the way for scientists to fix “faulty” DNA in humans, potentially wiping out inherited diseases for good. Here is all you need to know about the revolutionary CRISPR-Cas9 technique, what it means for future … Understanding how CRISPR works: The basicsGenetic Literacy Project Human Embryos Edited For The First Time In The US-Using CRISPRiGyaan Network (blog) |
Bloomberg |
China Regenerative’s Stem Cell Research Sparks Hope
Bloomberg Stem cells can become just about any sort of tissue, if cultivated correctly. With so many potential applications, the companies that perfect the use of stem cells first will stake a claim on massive profits. Hong Kong’s China Regenerative Medicine is … |
Xconomy |
Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More
Xconomy Gene editing took an important step this week when a group of U.S. researchers used CRISPR-Cas9 technology to correct a genetic error in dozens of human embryos without complications. It’s a significant achievement, but amidst the hype, it’s worth … |
|
Kite assesses EU manufacturing options as it submits CAR–T therapy for review
BioPharma-Reporter.com The submission is the first in Europe of a chimeric antigen receptor (CAR) T-cell therapy and as such Kite is now evaluating manufacturing options in Europe, a spokesperson from the firm told Biopharma-Reporter. Kite’s principle manufacturing facility … |
|
Kite assesses EU manufacturing options as it submits CAR–T therapy for review
BioPharma-Reporter.com The submission is the first in Europe of a chimeric antigen receptor (CAR) T-cell therapy and as such Kite is now evaluating manufacturing options in Europe, a spokesperson from the firm told Biopharma-Reporter. Kite’s principle manufacturing facility … |
Deutsche Welle |
Fipronil contamination scare: Aldi pulls all eggs from shelves in Germany
Deutsche Welle Food from labs for a sustainable future? “Bio-hacking” makes it possible to produce milk without cows and eggs without chickens. So-called synthetic biology could revolutionize food systems to more sustainably feed 7 billion, says bio-hacker Hannes … |